Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03837899
Title Durvalumab and Tremelimumab for Pediatric Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: child
Covered Countries USA


No variant requirements are available.